Phaseline

Companies › Eccogene

Eccogene: clinical trials, targets and expected readouts

2 active drug programs in 5 registered trials: 3 Phase 2, 2 Phase 1; Metabolic and endocrine, Gastroenterology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
ECC4703
Thyroid hormone receptor beta isoform (THRβ) agonist
NR1H3Phase 2Adult Obesity; Metabolic Dysfunction-associated Steatohepatitis; Non-alcoholic Fatty Liver Disease (NAFLD); Metabolic Dysfunction-Associated SteatohepatitisDec 2026
ECC0509
Semicarbazide sensitive amine oxidase (SSAO) inhibitor
AOC3Phase 2Metabolic Dysfunction-associated SteatohepatitisSep 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07505303ECC4703Phase 2Adult ObesityMetabolic and endocrineOct 2026
NCT07726368ECC4703Phase 1Non-alcoholic Fatty Liver Disease (NAFLD)GastroenterologyDec 2026
NCT07334080ECC4703Phase 1Metabolic Dysfunction-Associated SteatohepatitisMetabolic and endocrineApr 2027
NCT07288138ECC4703Phase 2Metabolic Dysfunction-associated SteatohepatitisMetabolic and endocrineSep 2027
NCT07288138ECC0509Phase 2Metabolic Dysfunction-associated SteatohepatitisMetabolic and endocrineSep 2027

Targets

NR1H3 (1) AOC3 (1)

Companies with the same targets

–

Companies built like this

Marea Therapeutics Rivus Pharmaceuticals Rare Thyroid Therapeutics International Eddingpharm (Zhuhai) Ribotek Biopharmaceuticals (Shandong)

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.